NASDAQ:BRTX BioRestorative Therapies (BRTX) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free BRTX Stock Alerts $1.38 +0.01 (+0.73%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$1.33▼$1.4150-Day Range$1.23▼$1.4852-Week Range$1.20▼$7.13Volume64,526 shsAverage Volume652,361 shsMarket Capitalization$9.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get BioRestorative Therapies alerts: Email Address BioRestorative Therapies MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 5 Articles This WeekInsider TradingAcquiring Shares$1,981 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.96) to ($1.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.54 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for BioRestorative Therapies.Read more about BioRestorative Therapies' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.46% of the float of BioRestorative Therapies has been sold short.Short Interest Ratio / Days to CoverBioRestorative Therapies has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioRestorative Therapies has recently increased by 322.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioRestorative Therapies does not currently pay a dividend.Dividend GrowthBioRestorative Therapies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BRTX. Previous Next 3.0 News and Social Media Coverage News SentimentBioRestorative Therapies has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for BioRestorative Therapies this week, compared to 0 articles on an average week.Search Interest2 people have searched for BRTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows5 people have added BioRestorative Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioRestorative Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,981.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders21.60% of the stock of BioRestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.38% of the stock of BioRestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioRestorative Therapies' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioRestorative Therapies are expected to grow in the coming year, from ($1.96) to ($1.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioRestorative Therapies is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioRestorative Therapies is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioRestorative Therapies has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhat’s Really Next for America…Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly.Click here to stream this controversial exposé now. About BioRestorative Therapies Stock (NASDAQ:BRTX)BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Read More BRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRTX Stock News HeadlinesMay 15 at 4:49 AM | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Provides First Quarter 2024 Business UpdateMay 14 at 4:10 PM | globenewswire.comBioRestorative Therapies Provides First Quarter 2024 Business UpdateMay 12, 2024 | americanbankingnews.comBioRestorative Therapies (BRTX) Set to Announce Earnings on TuesdayMay 8, 2024 | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting ObesityMay 8, 2024 | globenewswire.comBioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting ObesityApril 30, 2024 | globenewswire.comBioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024April 30, 2024 | globenewswire.comBioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics TechnologyApril 16, 2024 | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol AmendmentApril 16, 2024 | theglobeandmail.comBiotech Catches Major Premarket Bid Following FDA ClearanceApril 16, 2024 | marketwatch.comBioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol AmendmentApril 16, 2024 | msn.comBioRestorative gains as FDA clears amendment to study on cell therapy candidateApril 16, 2024 | globenewswire.comBioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol AmendmentApril 12, 2024 | investing.comBioRestorative Therapies VP buys shares worth over $10,000April 8, 2024 | globenewswire.comBioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc DiseaseApril 3, 2024 | globenewswire.comBioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued WarrantsApril 3, 2024 | finance.yahoo.comBioRestorative Therapies Full Year 2023 Earnings: Beats ExpectationsApril 1, 2024 | globenewswire.comBioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-KMarch 12, 2024 | msn.comBioRestorative engages advisory firm for clinical application of cell therapy BRTX-100March 11, 2024 | globenewswire.comBioRestorative Therapies to Participate in the 36th Annual ROTH ConferenceFebruary 15, 2024 | finance.yahoo.comFavourable Signals For BioRestorative Therapies: Numerous Insiders Acquired StockFebruary 14, 2024 | finance.yahoo.comBioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual MeetingFebruary 9, 2024 | msn.comBioRestorative Therapies Sparks Investor Interest with New TransactionFebruary 9, 2024 | msn.comBioRestorative Therapies Secures $8.1M Through Warrant RestructuringFebruary 6, 2024 | marketwatch.comShares of BioRestorative Therapies Fall to Four-Year Low on Exercise of Warrants, New IssueFebruary 6, 2024 | msn.comWhy BioRestorative Therapies (BRTX) Stock Is Down 55%See More Headlines Receive BRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today5/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:BRTX CUSIPN/A CIK1505497 Webwww.biorestorative.com Phone631-760-8100FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,410,000.00 Net Margins-9,873.97% Pretax Margin-9,886.83% Return on Equity-114.84% Return on Assets-107.19% Debt Debt-to-Equity RatioN/A Current Ratio10.72 Quick Ratio10.72 Sales & Book Value Annual Sales$150,000.00 Price / Sales62.28 Cash FlowN/A Price / Cash FlowN/A Book Value$2.45 per share Price / Book0.56Miscellaneous Outstanding Shares6,770,000Free Float5,308,000Market Cap$9.34 million OptionableNot Optionable Beta62.12 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Lance Alstodt (Age 53)Chairman of the Board, President & CEO Comp: $954.17kMr. Robert Eugene Kristal (Age 56)Chief Financial Officer Comp: $368.12kMr. Francisco J. Silva (Age 49)Chief Scientist, VP of Research & Development, Secretary and Director Comp: $891.67kMr. Robert Paccasassi (Age 55)Vice President of Quality Assurance & Regulatory Compliance Comp: $233.95kDr. Wayne J. Olan M.D.Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory BoardKey CompetitorsOntrakNASDAQ:OTRKMangoceuticalsNASDAQ:MGRXGreenbrook TMSNASDAQ:GBNHFUniverse PharmaceuticalsNYSE:UPCPrecipioNASDAQ:PRPOView All CompetitorsInsiders & InstitutionsStoneX Group Inc.Bought 34,850 shares on 5/1/2024Ownership: 0.515%Francisco SilvaBought 1,708 shares on 4/8/2024Total: $1,981.28 ($1.16/share)Dale BroadrickBought 86,041 shares on 2/9/2024Total: $113,574.12 ($1.32/share)Dale BroadrickBought 36,374 shares on 2/7/2024Total: $50,196.12 ($1.38/share)Dale BroadrickSold 250 sharesTotal: $470.00 ($1.88/share)View All Insider TransactionsView All Institutional Transactions BRTX Stock Analysis - Frequently Asked Questions How have BRTX shares performed in 2024? BioRestorative Therapies' stock was trading at $1.7399 at the beginning of 2024. Since then, BRTX shares have decreased by 20.7% and is now trading at $1.38. View the best growth stocks for 2024 here. How were BioRestorative Therapies' earnings last quarter? BioRestorative Therapies, Inc. (NASDAQ:BRTX) posted its quarterly earnings results on Friday, March, 29th. The company reported ($0.57) EPS for the quarter. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.03 million. BioRestorative Therapies had a negative net margin of 9,873.97% and a negative trailing twelve-month return on equity of 114.84%. Who are BioRestorative Therapies' major shareholders? BioRestorative Therapies' stock is owned by many different retail and institutional investors. Top institutional investors include StoneX Group Inc. (0.51%). Insiders that own company stock include Dale Broadrick, Francisco Silva and Lance Alstodt. View institutional ownership trends. How do I buy shares of BioRestorative Therapies? Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BRTX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsThe 1,000X Crypto PlaybookTrue Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityThe #1 Crypto for AIWeiss RatingsWhy Is Gold On a MASSIVE rally? Huge AlertsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioRestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
